Published price vs quote-only
Shed vs Embody: Which One Publishes Its Price? (2026)
Compare Shed and Embody on real cost over 12 months, medication type, price stability and support. Independent 2026 analysis, no first-month gimmicks.
Published · Pricing as published in our provider dataset, synced · Editorial scores 9.9 and 7.6 out of 10
We may receive compensation when you click partner links. Rankings are based on research methodology, not sponsorship.
Both Shed and Embody will get a GLP-1 prescription to your door without an in-person visit. The question is what the year after that first shipment looks like.
Embody publishes what it charges — Semaglutide $69/mo (was $299), tirzepatide $119/mo. Shed does not: Shed does not publish standard pricing; you receive a personalized quote after completing the intake assessment. That asymmetry is the comparison, because you can only price-check one of these two before handing over a medical history.
This comparison works from what each provider publishes: the entry price, what it becomes at month two, the medication actually dispensed, and what is bundled rather than billed. Every figure traces back to the provider's own published material, and the missing ones stay missing.
The short answer
- Easier to price in advance
- Embody — Semaglutide $69/mo (was $299), tirzepatide $119/mo. The other side quotes after intake, so a like-for-like total is not available before you apply.
- FDA-approved medication
- Shed — The only side that can write an approved brand-name product at all — it offers name-brand FDA-approved GLP-1 and compounded GLP-1.
- Tirzepatide access
- Embody — Tirzepatide at $119/mo; the other side publishes semaglutide only.
- Most support included
- Shed — Continuous coaching built into every treatment plan.
Shed and Embody, side by side
Nothing in this table is our estimate. Where a provider does not publish something, the cell says so.
| Shed | Embody | |
|---|---|---|
| Advertised price | 10% off the first month, price quoted after intake | Semaglutide $69/mo (was $299), tirzepatide $119/mo |
| Rate after promotions | not published before intake | $69/mo |
| Pricing structure | Quoted only after intake | Published rate per medication |
| Medication | Name-brand FDA-approved GLP-1 and compounded GLP-1 | Compounded semaglutide and compounded tirzepatide |
| Price transparency | Quote only, after intake | Published upfront |
| Payment options | Card only, no financing published | Card only, no financing published |
| Shipping | Home delivery after clinician review | Free shipping, 1-2 day delivery after approval |
| Support model | Coaching built into the plan | No coaching program stated |
| Tirzepatide | Not published | $119/mo |
| Patient reviews | 8,500 | 11,250 |
| eRxDoctor score | 9.9/10 | 7.6/10 |
Shed vs Embody on total cost, not entry price
The advertised rate answers the wrong question. Here is what each one costs across a realistic course of treatment, on published pricing.
| Shed | Embody | |
|---|---|---|
| First month | Not published | $69 |
| Months 2 onward | Not published | $69/mo |
| 6-month total | Not computable | $414 |
| 12-month total | Not computable | $828 |
| Best published plan | No multi-month discount published | No multi-month discount published |
A like-for-like annual total is not available for Shed: Shed does not publish standard pricing; you receive a personalized quote after completing the intake assessment. Treat any comparison that quotes one as an estimate someone else has made for you.
One publishes a price. One does not.
Embody publishes Semaglutide $69/mo (was $299), tirzepatide $119/mo before intake. That is the baseline condition for comparing two programs at all.
Shed runs the other way around — Shed does not publish standard pricing; you receive a personalized quote after completing the intake assessment. There are defensible reasons for that; personalized plans genuinely do vary. The practical effect is still that you cannot comparison-shop it, and a completed intake is exactly the moment a quote lands with the most leverage.
If you do go through Shed's intake, ask for the month-two price in writing before you pay for month one. That single question resolves most of the disclosure gap.
Shed in detail
Shed offers both name-brand and compounded GLP-1 weight loss medications with integrated coaching, a 2-minute approval assessment, and 10% off your first month.
Intake is 2-minute approval assessment. Fulfillment is home delivery after clinician review. The commercial terms are quoted only after intake, quote only, after intake.
Support: continuous coaching built into every treatment plan. The medications on offer are name-brand FDA-approved GLP-1 and compounded GLP-1.
Shed pros
- Flexibility to choose medication type based on budget and needs
- Continuous coaching is integrated into treatment, not just a prescription
- Offers both FDA-approved name-brand GLP-1 and compounded options on one platform
- 10% off your first month for new patients
Shed cons
- Standard pricing is not published, you receive a personalized quote after intake
- Coaching-bundled model can cost more than bare-prescription platforms
- Name-brand options carry significantly higher costs than compounded alternatives
Read next to Embody, the weak point: you cannot know what you will pay until you have finished the intake.
How Embody works
Embody positions itself on the lowest published semaglutide price on this list, with no lock-in. Semaglutide $69/mo (was $299), Tirzepatide $119/mo
Practically: licensed provider review handled entirely online, free shipping, 1-2 day delivery after approval, and a pricing model that is published rate per medication.
Ongoing care is 24/7 support for dosing and side-effect questions, and the medication list runs to compounded semaglutide and compounded tirzepatide.
Embody pros
- Lowest entry price on this list at $69/month for compounded semaglutide
- Compounded tirzepatide available at $119/month
- Free shipping with fast 1–2 day delivery after approval
- No long-term commitment; cancel without penalty
Embody cons
- Fewer premium features (no integrated coaching or advanced monitoring) than higher-priced platforms
- Compounded medication only, no branded Ozempic, Wegovy, or Zepbound
- $69 semaglutide pricing is a limited-time offer that may increase
The reservation worth holding, particularly next to Shed: a limited-time rate with few of the extras that higher-priced platforms bundle.
Shed or Embody: matching the program to the patient
Choose Shed if:
- delivery works the way you want it to: home delivery after clinician review
- you want to start on their timeline: 2-minute approval assessment
- you want continuous coaching built into every treatment plan rather than a prescription alone
- you want an FDA-approved finished medication rather than a compounded preparation
Choose Embody if:
- you want the full price in front of you before completing an intake
- you want tirzepatide available without changing provider later
- the level of clinical contact suits you: 24/7 support for dosing and side-effect questions
- the feature you would actually use: the lowest published semaglutide price on this list, with no lock-in
The trade-offs, stated plainly
On price. Only Embody publishes a rate you can plan against (Semaglutide $69/mo (was $299), tirzepatide $119/mo). The other quotes after intake, which is a cost of a different kind: you cannot budget the year in advance.
On predictability. Quoted only after intake at Shed, against published rate per medication at Embody. The more predictable structure is worth a premium to anyone who has been surprised by a telehealth invoice before.
On access. Shed advertises 2-minute approval assessment and home delivery after clinician review; Embody advertises licensed provider review handled entirely online and free shipping, 1-2 day delivery after approval. Neither publishes its state coverage, so confirm you are eligible before paying for anything.
On medication. Shed covers name-brand FDA-approved GLP-1 and compounded GLP-1; Embody covers compounded semaglutide and compounded tirzepatide. Only Embody publishes a tirzepatide route, which matters if semaglutide underdelivers.
The clinical evidence, separated from the marketing
Both platforms sell access to the same drug class, so the clinical record below applies equally to each.
NIDDK frames medication as one component of obesity treatment rather than a replacement for the rest of it, per NIH, NIDDK.
SURMOUNT-4 found that continuing tirzepatide maintained and extended weight reduction, while withdrawing it led to substantial regain, per JAMA, SURMOUNT-4.
Use it as the floor for the conversation with whichever prescriber you end up with, rather than as a reason to pick one platform over the other.
Shed vs Embody: common questions
What happens when Embody's promotional price ends?
The rate moves to $69/mo, a 0% increase on the advertised entry price. Budget from that number rather than the headline, because it is the one you will pay for eleven of your first twelve months.
Can I switch from Shed to Embody later?
Yes. Neither program locks you in clinically, and both operate month to month unless you have bought a multi-month plan. Practically, switching means a fresh intake, a fresh clinician review and possibly a gap in supply, so time it against your current shipment rather than your renewal date.
Which has more patient reviews, Shed or Embody?
Embody, with 11,250 against 8,500. Ratings across this market cluster tightly, so volume is the more useful signal: it indicates how much operational load the platform has already absorbed, not how good the medication is.
Is coaching included with Shed or Embody?
Shed includes continuous coaching built into every treatment plan in the monthly price. Embody provides 24/7 support for dosing and side-effect questions, without a separate coaching program. If medication alone has failed you before, the bundled version is the one to price properly rather than the one to cut.
Do Shed or Embody take insurance?
Both run on a direct-pay basis: you pay the platform and it does not bill your insurer. Neither publishes HSA/FSA acceptance, so budget the full amount as out-of-pocket spending.
The verdict
Neither of these two publishes enough for a clean cost verdict, which is itself the finding. Shed leads on one of the few platforms that will write either a name-brand or a compounded GLP-1, with coaching bundled into the plan rather than sold beside it; Embody leads on the lowest published semaglutide price on this list, with no lock-in.
Before choosing either, get the maintenance-dose price in writing. Without it, any comparison — including this one — is working with half the information.
Get the maintenance-dose price in writing from whichever one you pick. That single question prevents most of the regret in this category.
Keep comparing
- Shed vs DirectmedsBrand-name vs compounded
- Shed vs MeasuredPublished price vs quote-only
- Embody vs TMatesBudget vs premium
- Embody vs Elevate HealthBudget vs premium
- Directmeds vs TMatesPublished price vs quote-only
- Directmeds vs He & She MDPublished price vs quote-only
See every provider in context on the weight loss rankings, or browse the full comparison index.
Disclaimers and methodology
Medical content is informational only and does not replace professional diagnosis, treatment, or emergency care.
Some links are affiliate links and may generate commission at no extra cost to you.
Pricing reflects what each provider published as of the sync date above and changes frequently; confirm the current rate, and the rate at your maintenance dose, before you pay. Six- and twelve-month totals are calculated from those published rates and exclude anything a provider bills separately.
eRxDoctor is an independent publisher. It is not a medical provider, is not affiliated with or endorsed by Shed or Embody, and does not sell treatment. Read our ranking methodology.